Expression from a short human cytomegalovirus (HCMV) major immediate early (IE) promoterenhancer was tested in three different virus vectors : recombinant adenovirus (Ad), recombinant herpes simplex virus type 1 (HSV-1) and HSV-1-derived amplicon vectors. The HCMV major IE promoterenhancer within a replication-deficient recombinant Ad vector was shown to produce cell-specific expression in rat nervous system cell cultures. Recombinant Ad entered all cell types examined but the HCMV major IE promoter was silent in primary cultures of neocortical neurons and Schwann cells, although it drove transgene expression in astrocytes and fibroblasts. Moreover, in neurons and Schwann cells, expression from the HCMV major IE
Introduction
The study of promoter function within neuronal cells has been hampered by the lack of a reliable system to transfer promoter-reporter gene constructs into post-mitotic neurons. Virus vectors have thus been proposed as useful tools to analyse cell type-specific expression within identified brain cell types. We utilized replication-deficient adenovirus (Ad) recom- Fig. 1. The HCMV major IE promoter-enhancer used in the vector RAd35 extends from k299 to j69. The enhancer element contains a mixed series of direct repeats. This version of the promoter contains 2/3 copies of the 16 bp repeat, 3/4 copies of the 18 bp repeat, 2/5 copies of the 19 bp repeat and 0/2 copies of the 21 bp repeat. The 19 bp repeat is thought to bind ATF/CREB, the 18 bp repeat NF-κB and one of the 18bp repeats (marked 18*), AP1. Binding sites for Sp1 and a leader transcription factor-binding protein (LTF) are indicated as is the unique sequence region (usr). The upstream modulator sequence and the 21 bp repeats have both been found to have a negative effect on expression in certain cell lines and are absent from the construct. The transcription factor YY1 is believed to act on the 21 bp repeat (Liu et al., 1994) . The promoter contains a partial copy of a 21 bp repeat (k296 to k316). & Akrigg, 1991) . This promoter sequence is known to induce significantly higher levels of expression in undifferentiated teratocarcinoma cells (Kothari et al., 1991) , the monocytic cell line THP1 (Sinclair et al., 1992) and human fibroblasts, than versions of the promoter that contain additional upstream sequences from the enhancer and modulator region (J. H. Sinclair, Univeristy of Cambridge, Cambridge, UK, personal communication ; A. Akrigg & G. W. G. Wilkinson, unpublished results) . Interestingly, a recent report (Baskar et al., 1996) demonstrated cell type-specific expression in the brain of transgenic mice using a promoter derived from the HCMV major IE promoter-enhancer containing nucleotides k670 to j54. Replication-deficient adenovirus (RAd) vectors provide an efficient tool for both in vitro and in vivo gene transfer into brain cells (Akli et al., 1993 ; Bajocchi et al., 1993 ; Byrnes et al., 1995 ; Davidson et al., 1993 ; Le Gal La Salle et al., 1993) . Ad vectors have low intrinsic neurotoxicity and give low-level, possibly cell-and tissue-specific expression of virus genes after low multiplicity infections Yang et al., 1994) ; they also provide efficient nuclear targeting of vector DNA and high-level expression. Long-term gene expression can be achieved in vitro, in immunosuppressed animals in vivo or by further reduction of vector immunogenicity. Importantly, following infection of the brain with Ad vectors in vivo, an immune response against vector and transgene can be detected, which limits long-term expression (Byrnes et al., 1995 (Byrnes et al., , 1996 .
Cell type-specific promoters have been used to target gene expression to identified cell types using Ad vectors (Babiss et al., 1986 ; Besserau et al., 1994 ; Hayashi et al., 1994) . However, the potential of this approach to restrict transgene expression remains to be fully explored Fisher et al., 1996) . Furthermore, studies of gene transfer into the lung (Grubb et al., 1994) and muscle (Kass-Eisler et al., 1994) using Ad vectors have shown a differential transduction rate in different target cells. In addition, the activity of a simian virus 40 promoter in HSV-1 vectors was shown to depend on various factors including its position within the vector, the target cell type and the presence of other virus proteins (Roemer et al., 1991) .
We have characterized the capacity of a particular promoter to drive the expression of a reporter gene expressed from within various virus vectors. Expression in identified neuronal cell types was assessed by double-labelling immunocytochemistry to detect both the transgene and individual brain cell type markers. Expression from an RAd (E1 − \E3 − ) containing lacZ under the control of a truncated HCMV major IE promoter was detected in astrocytes but not in neurons or Schwann cells. However, the same promoter construct could be activated by superinfection with several wild-type (Ad5, HCMV) or replication-deficient viruses (HSV-1 tsK), and was active in neurons when expressed from within a recombinant HSV-1-derived vector. The truncated HCMV major IE promoter within an RAd vector thus provides an efficient system to target expression to a subset of brain cells in culture. The mechanism responsible for cell-specific expression was investigated and its implications for achieving brain cell type-specific expression using virus vectors, and neurological gene therapy are discussed.
Methods Viruses
HSV-1. Strain tsK is an HSV-1 mutant containing a temperature-sensitive mutation in the gene encoding the IE protein ICP4, with a permissive temperature of 31 mC and a non-permissive temperature of 38n5 mC. Specific expression from HCMV promoter Specific expression from HCMV promoter major IE promoter (k299 to j69) driving lacZ, within the US5 locus of HSV-1.
HSV-1-derived amplicons. The short HCMV major IE promoter (k299 to j69) driving lacZ was inserted into an amplicon plasmid (pA-HCMV-lacZ) containing HSV-1 packaging and replication sequences (Lowenstein et al., a, 1995 . Amplicon names indicate the amplicon plasmid followed by the helper virus used to package HSV-1 amplicons : (i) pA-HCMV-lacZ\wt (wild-type 17 + ) ; and (ii) pA-HCMVlacZ\D30EBA (an ICP4 − mutant). D30EBA (Paterson & Everett, 1990) was grown in E5 trans-complementing cells (DeLuca et al., 1985) .
HCMV. Wild-type HCMV strain AD169 was used.
Adenoviruses. Wild-type Ad5 was used ; Ad E1\E3-deleted vectors RAd122, RAd35, RAd31 and Ad.RSVβgal were derived as shown in Fig. 2 and\or as described earlier (Akrigg et al., 1985 ; Akli et al., 1993 ; Wilkinson & Akrigg, 1991 . RAd122 contains the Rous sarcoma virus (RSV) LTR driving lacZ ; RAd35 contains the truncated HCMV major IE promoter driving lacZ ; Ad.RSVβgal contains the RSV LTR driving lacZ to which a nuclear localization signal (nls) had been added (kindly provided by M. Perricaudet, Institut Gustave Roussy, Paris, France) ; RAd31 contains the truncated HCMV major IE promoter driving the IE1 gene of HCMV. Fig. 1 shows in detail the structure of the truncated HCMV major IE promoter utilized and the cis-acting sites contained within the sequences (Akrigg et al., 1985 ; Boshart et al., 1985 ; Jeang et al., 1987 ; Liu & Stinski, 1992 ; Liu et al., 1994 ; Sambucetti et al., 1989 ; Stamminger et al., 1990 ; Thomsen et al., 1984 ; Wilkinson & Akrigg, 1991) .
Primary cultures of neurons, astrocytes and Schwann cells.
Cerebral cortex was dissected from day 17-18 embryonic rat brain and neurons were prepared as described earlier (Lowenstein et al., a, b, 1995 . Briefly, cortical neurons were dissociated, trypsinized, triturated and plated onto poly--lysine-treated coverslips in neuronal plating medium [Eagle's MEM with Earle's salts (Sigma) ; 600 mg\l glucose (BDH) ; 10 % (v\v) horse serum (Sigma) ; 100 U\ml penicillin and 100 µg\ml streptomycin (Sigma)]. Neurons were plated at a density of 0n5-2n0i10& cells\cm#. Cell survival was greater than 85 % as assessed by Trypan blue exclusion and the Live\Dead Viability kit (Molecular Probes). Astroglial cultures were taken from day 1-2 postnatal pup cortex and prepared as described by Banker & Goslin (1991) . Schwann cell cultures were prepared as described by Morgan (1996) . For superinfections with herpesviruses, virus was adsorbed to neuronal cultures 60 h after infection with Ad viruses and cells were processed 12-18 h later ; expression from HSV-1 vectors could be detected by 4-8 h post-infection. For co-infections with two different Ad vectors, both types of particles were added simultaneously to cultures and cells were processed 72 h later. In all superinfection and co-infection experiments a control consisting of cells infected with RAd35 only was included. Following infection of rat neurons with Ad5, low levels of late proteins (detected by immunocytochemistry using anti-hexon and anti-100 kDa non-structural scaffolding protein antibodies) were identified (data not shown), suggesting that Ad5 DNA replication and limited virus multiplication may occur in rat neuronal cells in culture. Ad5 and E1 − \E3 − RAd vectors were titrated on trans-complementing 293 cells. HSV-1-derived viruses were titrated on BHK-21 cells.
Immunocytochemistry and antibodies. Neurons were identified using MAbs (Sigma) diluted 1 : 500 or polyclonal anti-microtubuleassociated protein 2 (MAP-2) antibodies (kindly supplied by I. Fischer, Medical College of Pennsylvania, Philadelphia, Penn., USA) diluted 1 : 200 ; astrocytes were labelled using MAbs and polyclonal anti-glial fibrillary acidic protein (GFAP) antibodies (Sigma) at 1 : 200 ; Schwann cells were immunolabelled with either anti-NGF-R (p75 ; low affinity nerve growth factor receptor) MAbs (Boehringer Mannheim) at 1 : 100 or polyclonal anti-S-100 (cytoplasmic EF-hand Ca# + binding protein) antibodies (Dakopatts) at 1 : 1000. The antibodies used to identify fibroblasts were mouse anti-Thy1.1 MAbs (R. Morris, National Institute for Medical Research, London, UK) diluted 1 : 1000. Mouse anti-β-galactosidase (β-gal) MAbs (Promega) at 1 : 5000 or rabbit polyclonal anti-β-gal antibodies (J. Price, SmithKline Beecham, Harlow, UK) at 1 : 1000 were used to detect β-gal. Undiluted MAb culture supernatant from anti-E1a MAbs (E. Harlow, MIT, Boston, Mass., USA) was used to detect E1a ; mouse anti-HSV-1 gD MAbs (T. Minson, University of Cambridge, Cambridge, UK) were used diluted 1 : 2 ; rabbit polyclonal anti-HSV-1 ICP47 antibody (H. Marsden, MRC Virology Unit, Glasgow, UK) was used at 1 : 500 ; mouse anti-HCMV IE1 MAb (B. Rogers, Murex Diagnostics, Dartford, UK) was used at 1 : 500. Anti-Ad late protein antibodies (I. Sharp, Public Health Laboratory Service, London, UK) were used as follows : mouse anti-hexon MAb (LP5.1), 1 : 1000 ; mouse anti-100 kDa non-structural scaffolding protein MAb (8\199.1), 1 : 1000 (Russell et al., 1981) .
In experiments with amplicon vectors, we examined three populations of cells : (i) cells infected solely by the amplicon ; (ii) cells doubly infected by the amplicon and helper virus ; and (iii) cells solely infected by the helper virus, as described earlier (Lowenstein et al., a, 1995 . Double immunocytochemical labelling was performed using antibodies against β-gal (to detect expression of the lacZ gene encoded by amplicons) and gD to detect gene expression from the helper virus pA-HCMV-lacZ\wt, or antibodies against the IE protein ICP47 to detect gene expression from the helper virus pA-HCMV-lacZ\D30EBA.
The following secondary antibodies were used in this study : fluorescein isothiocyanate (FITC)-or rhodamine-conjugated rabbit antimouse antibody (Dakopatts), rhodamine-conjugated swine anti-rabbit antibody (Dakopatts), fluorescein-conjugated goat anti-mouse antibody (Pierce & Warriner), fluorescein-conjugated swine anti-rabbit antibody (Dakopatts) and rhodamine-conjugated goat anti-mouse antibody (Jackson). They were utilized in appropriate combinations for either single or double label immunofluorescence.
For immunocytochemical (immunofluorescence) experiments cultures were briefly rinsed in pre-warmed PBS (37 mC) and then fixed for 20 min in 4 % paraformaldehyde, 0n12 M sucrose, in PBS pH 7n4. After washing the cultures with PBS, cells were permeabilized in 0n3 % Triton X-100 (BDH) in PBS for 5 min, rinsed and incubated in 10 % normal goat serum (NGS ; Vector) in PBS (blocking solution) for 1 h, washed once in 1 % (v\v) NGS in PBS, and then incubated with primary antibodies for between 1-2 h to overnight at 4 mC. Afterwards, cultures were washed in 1 % NGS in PBS and incubated with fluorescently labelled secondary antibodies for 2 h (diluted 1 : 50 or 1 : 100 in 1 % NGS in PBS). Cultures were then washed in PBS and mounted onto glass slides with 10 % MOWIOL 4-88 (Calbiochem) and 25 % glycerol (BDH) in 50 mM Tris-HCl pH 8n5.
Immunolabelled cultures were examined using an Olympus Vanox AHBS photomicroscope with brightfield illumination or with the Generation of recombinant viruses RAd122 (RSV LTR-lacZ) and RAd35 (HCMV major IE-lacZ). The transfer vector pMV60 was constructed from plasmid pXCX2 (Spessot et al., 1980) with the addition of a linker (containing the HindIII cloning site) at the unique XbaI cleavage site. The lacZ gene was cloned into pMV60 under RSV promoter control and upstream of a poly(A) signal on a HindIII expression cassette (1-3900 bp ; in parentheses) to generate pMV60/lacZ. pMV35 was produced from pMV60 by insertion of the truncated HCMV major IE promoter, lacZ and a poly(A) signal (1-3650 bp ; in parentheses) into the HindIII site of pMV60 (Wilkinson & Akrigg, 1992) . The transfer vectors pMV60/lacZ and pMV35 provided the expression cassette inserted into the Ad E1 gene region ; small numbers on pMV60/lacZ and pMV35 refer to the Ad5 genomic sequence. Plasmid pJM17 contains the entire Ad5 dl309 genome with the prokaryotic vector pBRX (4400 bp Specific expression from HCMV promoter Specific expression from HCMV promoter fluorescent attachment AH2-RFL, and photographed using Kodak TMax3200 or Fuji 1600 film.
X-Gal histochemical assay. Cells were fixed with the same fixative used for immunocytochemical experiments, washed, permeabilized and incubated for 3 h at 37 mC in a solution containing 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl # and 1 mg\ml of the chromogen X-Gal (5-bromo-4-chloro-3-indolyl β--galactopyranoside). Following the incubation, cells were washed several times with PBS and mounted onto glass slides.
Experiments. Each experiment was repeated two to five times, apart from the infection of neuronal cultures with RAd35, which was repeated 20 times.
Results

Expression from RAd vectors in primary neocortical and peripheral nerve cultures
Primary cultures were infected with either (i) wild-type Ad5 ; (ii) RAd35 (truncated HCMV major IE promoter-lacZ); (iii) RAd31 (truncated HCMV major IE promoter-HCMV IE1) ; or (iv) RAd122 (RSV LTR-lacZ) and Ad.RSVβgal (RSV LTR-lacZ\nls). Three days later cultures were fixed and processed for the immunocytochemical detection of transgene expression (Figs 3 and 4) . Cell types present in the cultures were identified by double-label immunocytochemistry of infected cells using antibodies recognizing MAP-2, a neuronal microtubule-associated protein ; GFAP, an astrocyte-specific intermediate filament ; Thy1, a membrane protein located on fibroblasts (data not shown) ; and S-100 or NGF-R, two proteins expressed by peripheral nerve Schwann cells.
Primary neocortical cultures infected with RAd35 at an m.o.i. of 10 expressed β-gal in glial cells (Fig. 3 k, l ), but not in neurons (Fig. 3 c, d ). Such experiments were repeated 20 times using either specific anti-β-gal antibodies (Fig. 3 c, d ; Fig. 4 f, g ) or X-Gal histochemistry (Fig. 4 h, i ) . Neither method was able to detect any β-gal immunoreactivity or enzyme activity within neurons. Infection of cells with RAd31 (Wilkinson & Akrigg, 1992 ) also showed expression of the transgene (IE1 of HCMV) in glial cells but not in neurons (Fig. 4 a- 
e).
Cultures were also infected with Ad5 (m.o.i. of 10) and expression of E1a proteins was detected using specific antibodies recognizing E1a proteins. Both glial cells (Fig. 3 i, j ) and neurons (Fig. 3 a, b ) displayed positive nuclear E1a immunoreactivity, indicating that Ad5 can infect both glial cells and neurons. Thus Ad5 infection led to virus gene expression in neurons (Fig. 3 a, b ), whereas infection with either et al., 1988) . Either transfer vector (pMV60/lacZ or pMV35) and pJM17 were co-transfected into 293 cells. Homologous recombination between the plasmids results in the expression cassettes replacing both the E1 gene region, 402-3328 and the intervening prokaryotic vector. This resulted in the removal of 7326 bp (pBRX 4400 bp and 2926 bp of E1 gene region) and insertion of the lacZ expression cassette comprising 3900 bp (RSV-lacZ) or 3650 bp (HCMV major IE-lacZ). The recombinant pJM17 size was thus reduced sufficiently to be packaged into nucleocapsids, resulting in plaques in the 293 cell monolayer and generation of E1 − recombinant viruses RAd35 (HCMV major IE-lacZ) and RAd122 (RSV LTR-lacZ). A linear representation of the RAd genome is shown below, illustrating the position of the expression cassettes, RSVp-lacZ or HCMVp-lacZ. Fig. 3 c, d ; Fig. 4 f-i ) or RAd31 (Fig. 4 a-e) at equivalent m.o.i. did not.
RAd35 (
Given that virus gene expression in neurons was obtained after infection with Ad5, but not RAd35 or RAd31, we wished to examine whether Ad encoding a promoter sequence different from the truncated HCMV major IE promoter could drive the expression of β-gal in neurons. To do so, we generated RAd122 (containing lacZ under the transcriptional control of the RSV LTR). Infection of neurons and glial cells at an m.o.i. of 10 with RAd122 demonstrated clearly that both neurons (Fig. 3 e, f ) and astroglia (Fig. 3 m, n) expressed the transgene. A second Ad recombinant in which the RSV LTR controlled expression of lacZ containing an nls (Ad.RSVβgal) was as effective as RAd122 at expressing transgenes in neurons (Fig. 3 g, h ) and glial cells (Fig. 3 o, p) . Between 10 and 25 % of all target cells expressed gene products encoded by either the wild-type Ad5, RAd122 or Ad.RSVβgal. The rate of transduction was higher in glial cell cultures compared to neuronal cell cultures. In no experiments were any neurons or Schwann cells expressing the transgene encoded by either RAd35 or RAd31 detected.
After infecting Schwann cells, Ad5 expressed E1a proteins (Fig. 5 a, b) and both RAd122 and Ad.RSVβgal expressed β-gal (Fig. 5 e-g ). However, as in neurons, there was no detectable expression from the HCMV major IE promoter in RAd35 (Fig.  5 c, d ). Thus, using a RAd vector as a gene delivery system, the truncated HCMV major IE promoter was able to drive transgene expression in fibroblasts and glial cells in primary cell cultures but not in neurons or Schwann cells.
Effect of wild-type Ad5 co-infection, and HSV-1 and HCMV superinfection, on expression from the HCMV major IE promoter in RAd35
Expression of the HCMV major IE promoter within recombinant HSV-1 vectors. Previous experiments using HSV-derived vectors showed that a large HCMV major IE promoterenhancer fragment (k750 to j4 ; described in Stinski & Roehr, 1985) was transcriptionally active in neurons (P. R. Lowenstein & C. M. Preston, unpublished results). Thus, we examined whether the truncated HCMV major IE promoter could drive the expression of β-gal when inserted into an HSV-1 vector. The HSV-1 recombinant BE8 contains the identical truncated HCMV major IE promoter-lacZ expression cassette present in RAd35, within the US5 locus of the HSV-1 genome. In contrast to RAd35, HSV-1 BE8 expressed high levels of β-gal following infection of neurons (Fig. 5 h, i ) Following superinfection of RAd35-infected cells with HSV-1 tsK at both the permissive (31 mC) and non-permissive temperatures (38n5 mC), expression of β-gal in neurons (Fig. 5 j, k) and Schwann cells (Fig. 5 l, m) was detected. In RAd35-infected neurons and Schwann cells, the truncated HCMV major IE promoter must therefore be maintained in a state in which it can still be activated by an appropriate stimulus. The ability of HSV-1 tsK to stimulate expression from RAd35 at the non-permissive temperature suggests that this function can be provided by an HSV-1 virion component or IE gene product.
To determine whether an IE or tegument protein of HSV-1 (Preston et al., 1988) was responsible for the transactivation of the truncated HCMV major IE promoter-enhancer, we constructed HSV-1 amplicons containing an identical promoter-lacZ cassette. Two amplicon preparations were used : pA-HCMV-lacZ\wt (wild-type HSV-1 as helper virus) and pA-HCMV-lacZ\D30EBA [D30EBA (ICP4 − ) as helper virus] (Fig. 6) . By labelling infected cells with antibodies recognizing genes expressed either by the amplicon or the helper virus, we could distinguish cells infected by both virus types from those infected by a single virus. In the absence of helper virus co-infection we could detect no or extremely low levels of β-gal activity (Fig. 6 c, d, g, h) . However, in the presence of co-infection with either helper virus we detected high levels of β-gal expression, which filled the neuronal processes, similar to those encountered after infection of cells with recombinant BE8 or after RAd35 infection followed by HSV-1 tsK superinfection (Fig. 6 a-f ). This strongly suggests that an HSV-1 IE protein activates the short HCMV major IE promoter-enhancer in neurons. Thus, infections with BE8, superinfection of RAd35-infected neurons with HSV-1 and experiments using HSV-1 amplicons indicated that in neurons and Schwann cells, an HSV-1-encoded function or functions activated expression from the HCMV major IE promoter.
Effect of wild-type Ad5-RAd35 co-infection. Ad encodes a number of transcriptional transactivators, the best characterized of which is E1a (Shenk, 1996) . To determine whether transcriptional transactivators encoded by wild-type Ad5 could activate the short HCMV major IE promoter contained within RAd35, neurons were infected with RAd35 and coinfected with Ad5. RAd35 was used at an m.o.i. of 10 ; Ad5 was used at an m.o.i. of 10-100 for co-infections. In this coinfection paradigm neurons were shown to express both β-gal (encoded by RAd35) and neuronal markers (Fig. 7 d, e) , or nuclear E1a (encoded by Ad5) and β-gal (Fig. 7 a, b) . Thus, coinfection of neurons with RAd35 and Ad5 (but not RAd35 alone ; data not shown) allowed expression from the short HCMV major IE promoter within RAd35.
Effect of HCMV superinfection. In the HCMV genome the major IE promoter drives expression of a complex transcriptional unit, which by differential splicing leads to expression of the gene regions IE1 and IE2. To assess whether infection of neurons with HCMV could complement the lack of expression from RAd35, neurons were infected with RAd35 and super- 
Discussion
The main conclusions from our experiments can be summarized as follows : (i) a truncated HCMV major IE promoter within a non-replicating Ad vector (RAd35, RAd31) EFC Specific expression from HCMV promoter Specific expression from HCMV promoter type Ad5 and HCMV can infect and promote gene expression in neurons, astrocytes and Schwann cells.
Expression pattern of transgenes encoded by recombinant virus vectors : characterization of expressing cells
Our results highlight the importance of characterizing the neural cell type expressing transgenes after transduction with virus vectors. Although other groups have previously shown expression in the brain from an HCMV major IE promoter within Ad, cell types expressing transgenes were not characterized (Akli et al., 1993 ; Bajocchi et al., 1993 ; Byrnes et al., 1995 ; Davidson et al., 1993 ; Le Gal La Salle et al., 1993 ). Our results demonstrate that expression from the truncated HCMV major IE promoter in brain cultures depends both on the virus vector and the target brain cell type, but is independent of the transgene being expressed. Without identifying transduced cells with cell type-specific markers, the cell-specific pattern of transgene expression could easily remain unnoticed.
Also, in vivo experiments use very high concentrations of virus likely to achieve very high m.o.i. In further experiments using RAd35 (data not shown) we detected weak expression of β-gal in neurons when the input m.o.i. was 1000. Under such extreme conditions or in cells that express a function which can complement the E1a deletion (Imperiale et al., 1984 ; Spergel & Chen-Kiang, 1991) , the block provided by the E1a deletion may be overcome and gene expression could be activated nonspecifically ; there was indeed major cytotoxicity when neuronal cultures were infected with such a high m.o.i.
The truncated HCMV major IE promoter used in these experiments lacks some of the enhancer element, an upstream series of NF-1 binding sites (Jeang et al., 1987) and the upstream modulator region, which has a strong repressive effect, particularly in undifferentiated cell types (Kothari et al., 1991) . Theoretically, the truncated version of the HCMV IE promoter used in our experiments should function in a wider range of cell types. Somewhat surprisingly, in non-neuronal cells, the truncated enhancer element used in these experiments drove significantly higher levels of expression than promoters containing the complete enhancer (Kothari et al., 1991 ; Sinclair et al., 1992) . This may due to the deletion of cis-acting repressive elements such as the YY1 binding sites.
Furthermore, the physical conditions under which virus infections of primary cultures occur ought to be taken into account in the evaluation of our results. poly--lysine, laminin and polyornithine, which might favour virus attaching to the culture dish itself. It is thus important to consider that these factors can influence the total number of infected cells detected in primary cultures, and help to explain why even at an m.o.i. of 10, only 10-40 % of cells became infected.
Neuronal expression from promoters inserted within recombinant virus vectors
The main mechanism proposed to explain our results is to postulate the existence of a specific transcriptional inhibitor that acts on the truncated HCMV major IE promoter in neocortical neurons and Schwann cells to block expression of β-gal. Importantly, we showed that the HCMV major IE promoter provided cell type-specific expression when inserted into a RAd vector, but not within recombinant HSV-1. Also, the endogenous major IE promoter of HCMV was active after infection of neurons. The results demonstrating transactivation of the truncated promoter by HSV-1 tsK superinfection (at 38n5 mC) and strong expression of β-gal within neurons doubly infected with the amplicon and helper pA-HCMV-lacZ\ D30EBA, suggest that an HSV-1-derived IE protein, possibly ICP0, modifies the expression of the truncated HCMV major IE promoter within RAd35. However, low but detectable expression of β-gal was obtained after neurons were infected solely by amplicons pA-HCMV-lacZ\D30EBA or pA-HCMVlacZ\wt. This indicates that the truncated HCMV major IE promoter contains the necessary cis-acting elements to allow expression in neurons in the absence of major HSV-1 IE transcriptional activators, and thus suggests that stimulatory transcription factors needed to achieve expression from this promoter, possibly in conjunction with a virion factor(s), are present in neurons. How superinfection with HSV-1 or HCMV (Stow & Stow, 1989) or co-infection with Ad5 activate the HCMV major IE promoter is most likely explained by these viruses providing strong transcriptional activating functions that overcome the effect of the putative transcriptional inhibitor.
Understanding the function of virus promoters in neurons remains an important goal of neurovirology. We have shown that a specific promoter sequence inserted into RAd vectors remains silent until activated by a specific transactivator. The ability of HCMV and Ad to transactivate expression from RAd35 in neuronal cell types provides evidence that in RAd35-infected neurons the HCMV major IE promoter EFF A. F. Shering and others A. F. Shering and others A cell expressing β-gal (curved arrow in g) which is a neuron also expressing MAP-2 (curved arrow in h). A neuron not expressing β-gal is indicated by a straight arrow in (g) and (h) ; the phase contrast image of these cells is shown in (i ). (j, k) Glial cells can be co-infected by RAd35 and HCMV, but they do not need to be co-infected to express β-gal encoded by RAd35. Two glial cells (j ) express high levels of β-gal (curved and straight arrow), while a third only expresses very low levels of β-gal (arrowhead). The cell indicated by the curved arrow also expresses nuclear IE1 (co-infected by RAd35 and HCMV), while the others do not. The scale bar (l ) equals 100 µm.
remains in a state that is accessible to the transcriptional machinery of the host neurons. Thus, the effects of transactivating functions provided by the virus vector or helper virus on the activity of heterologous promoters encoded by the virus vector are illustrated in this work, and also by previous results from our group using HSV-1-derived amplicons (Lowenstein et al., a, 1995 . Caution ought to be exerted when attempting to determine cell type-specific expression of promoters using virus vectors (Kaplitt et al., 1994) , since helper virus (in the case of HSV-1 amplicons) or the virus vector itself can profoundly affect the activity of a promoter (Lowenstein et al., a, 1995 . Moreover, it is possible that efficient expression from the HCMV IE promoter in some cell types may be absolutely dependent on transactivation by virion components (Liu & Stinski, 1992) . That virus promoters can be cell type-specific, however, has also been described in in vitro (Lubon et al., 1989) and transgenic studies using the HCMV major IE promoter-enhancer (Baskar et al., 1996 ; Koedood et al., 1995) . Superinfection with HSV-1, co-infection with Ad5 and superinfection with HCMV could transactivate the truncated HCMV major IE promoter within RAd35 in neurons and Schwann cells. To explain the results of the Ad5 co-infection, one possible explanation is that the E1a or another Ad5 early gene product provide the transactivating function. Gene products encoded by both the E1a and E1b region have been shown to transactivate the HCMV major IE promoter (Cockett et al., 1991 ; Gorman et al., 1989 ; Olive et al., 1990 ; Shirahata et al., 1995) . Furthermore, the 13S product of E1a was shown to activate a truncated HCMV major IE promoter, as long as it contained at least one 19 bp repeat (Olive et al., 1990) ; the construct used in our work contains two.
Thus, the short HCMV major IE promoter-enhancer within RAd35 can be activated in neurons in trans by transcriptional activators provided by HSV-1 (possibly through expression of an IE protein such as ICP0), wild-type Ad5 (possibly E1a), or wild-type HCMV (possibly a transactivating tegument protein or IE1).
Implications for the use of virus vectors to study cell type-specific expression of promoters
Our data highlight the importance of identifying the precise brain target cell type expressing a transgene after infection of cells with recombinant virus vectors, to assess (i) efficiency of gene transfer into cell subtypes ; and (ii) levels of transgene expression in individual target cell types. This is necessary when assessing gene transfer both into neuronal cell cultures and into the brain in vivo. Our data also demonstrate that E1 − \E3 − Ad as a vector does not modify the activity of a promoter inserted into its genome. Furthermore, we can now take advantage of this system to develop novel Ad vectors that allow cell type-specific expression in the brain. The use of recombinant Ad to express transgenes specifically in glioma cells, which originate the vast majority of brain tumours and which can express transgenes encoded by RAd vectors (J. Rowe, P. R. Lowenstein & M. G. Castro, unpublished results) should allow us to obtain reduced neuronal toxicity owing to the lack of neuronal expression.
Brain cell type-specific expression ought to prove advantageous for the treatment of brain diseases using gene therapy. However, the finding that superinfection with wildtype herpesviruses and adenoviruses can transactivate a promoter within a RAd vector will need to be taken into account in any future studies of cell type-specific expression, especially when performing in vivo experiments, or any possible clinical trials of gene therapy. Importantly, viruses that we have shown to be active in superinfection and coinfection experiments are known to produce brain infections especially in immunocompromised patients, who might be treated by gene therapy. Our experiments also demonstrate that genes other than the promoter-transgene cassettes, encoded by and expressed from the virus vector, need to be taken into account in the design, evaluation and development of new virus-derived vectors for gene transfer and gene therapy. 
